You are about to enter another country or region-specific website
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on products or uses of those products that are not approved in other countries or regions.

Join Our Team

GenMark Diagnostics Acquires License to HCV Genotyping Patent Estate

CARLSBAD, Calif., Nov 02, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK),
a provider of automated, multiplex molecular diagnostic testing systems,
announced today that it has acquired a non-exclusive license to
Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the
United States. The agreement includes an option to extend the license on
a global basis. The financial terms of the license transaction were not
disclosed.

Infectious disease testing is currently one of the largest commercial
opportunities in molecular diagnostics. Laboratories with molecular
diagnostic capabilities routinely perform infectious disease tests for
Hepatitis C (HCV), Human Immunodeficiency Virus (HIV) and Human
Papillomavirus (HPV). HCV genotyping is a guideline-supported test
performed in combination with HCV screening and viral load testing, and
today laboratories in the US currently have limited technology options
to address their molecular testing needs in this area.

"We are very pleased to announce this licensing agreement with
Innogenetics for the rights to its HCV genotyping patent estate," stated
Chris Gleeson, Chairman and CEO of GenMark Diagnostics. "We believe that
this license will allow us to enter a market that is ideally suited to
our technology and will significantly increase the value of the XT-8
system for our customers."

"The addition of HCV genotyping to our test menu will likely accelerate
GenMark's expansion into the largest molecular diagnostics laboratories
in the United States," he added.

"We are pleased to have completed this licensing agreement with GenMark
Diagnostics. The combination of our global HCV genotyping patent estate
with GenMark's leading technology platform will provide additional
testing options for physicians and patients, and further demonstrates
our continuing commitment to leadership in infectious disease testing,"
stated Christiaan De Wilde, CEO of Innogenetics.

About GenMark Diagnostics, Inc.

GenMark Diagnostics, Inc., a provider of automated, multiplex molecular
diagnostic testing systems, detects and measures DNA and RNA targets to
diagnose disease and to optimize the treatment of patients and is
focused on developing and commercializing its eSensor detection
technology. GenMark's XT-8 System is designed to support a broad range
of molecular diagnostic tests with a compact and easy-to-use workstation
and self-contained, disposable test cartridges. GenMark has developed
five diagnostic tests for use with the XT-8 System, including its Cystic
Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia
Risk Test which have received clearance from the Food and Drug
Administration. www.GenMarkDx.com.

About Innogenetics, NV:

Innogenetics NV is an international biotechnology company headquartered
in Ghent, Belgium that develops and markets diagnostic products to
improve therapy management and patient health.

Innogenetics develops and markets a range of diagnostic assays in the
field of infectious diseases, genetic testing, transplantation,
neuro-degeneration and oncology, with a focus on molecular diagnostics
and multiparameter testing. Its products are sold in over 90 countries
through its 6 subsidiaries and a large number of distributors and it has
in excess of 3,700 customers. Innogenetics is a Fujirebio Inc company,
part of Miraca Holdings Inc. (ticker code 4544, Tokyo Stock Exchange,
First Section).